[an error occurred while processing this directive]|[an error occurred while processing this directive]
侵犯胸壁T3N0-1M0期NSCLC术后辅助放疗进展
穆娅莎·阿布力米提, 梁军
100021 北京,国家癌症中心/中国医学科学院北京协和医学院肿瘤医院放疗科
Research progress on postoperative radiotherapy for T3N0-1M0 non-small cell lung cancer with chest wall invasion
Muyasha·Abulimiti, Jun Liang
Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences,Peking Union Medical College, Beijing 100021,China
Abstract： Currently,lung cancer is the most common malignant tumor in the world. The local control (LC) rate is only 20%-40% for patients with local advanced non-small cell lung cancer (NSCLC).Hence,reducing the LC rate and enhancing the overall survival (OS) are pivotal research objectives. However,postoperative adjuvant treatment for patients with early NSCLC with chest wall invasion is still controversial. In this article,the research progress on T3N0-1M0 NSCLC with chest wall invasion was reviewed from the perspectives including anatomical features,types of resection,patterns of failure and postoperative radiotherapy,etc.
Muyasha·Abulimiti,Jun Liang. Research progress on postoperative radiotherapy for T3N0-1M0 non-small cell lung cancer with chest wall invasion[J]. Chinese Journal of Radiation Oncology, 2018, 27(4): 416-419.
[1] Le Chevalier T,Arriagada R,Quoix E,et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer:first analysis of a randomized trial in 353 patients[J].J Natl Cancer Inst,1991,83(6):417-423.DOI:10.1093/jnci/83.6.417. [2] Aupérin A,Le Péchoux C,Rolland E,et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J].J Clin Oncol,2010,28(13):2181-2190.DOI:10.1200/JCO.2009.26.2543. [3] Dautzenberg B,Arriagada R,Chammard AB,et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma[J].Cancer,1999,86(2):265-273.DOI:10.1002/(SICI)1097-0142(19990715)86:2<265::AID-CNCR10>3.0.CO;2-B. [4] Facciolo F,Cardillo G,Lopergolo M,et al. Chest wall invasion in non-small cell lung carcinoma:a rationale for en bloc resection[J].J Thorac Cardiovasc Surg,2001,121(4):649-656.DOI:10.1067/mtc.2001.112826. [5] Caruana EJ,Solli P,Coonar AS.Hybrid video-assisted thoracoscopic surgery lobectomy and en-bloc chest wall resection for non-small cell lung cancer[J].J Thorac Dis,2016,8(9):E935-E937.DOI:10.21037/jtd.2016.08.24. [6] Santos HTA,Lope AJ,Higa C,et al. Lung cancer with chest wall invasion:retrospective analysis comparing en-bloc resection and′resection in bird cage′[J].J Cardiothorac Surg,2014,9:57.DOI:10.1186/1749-8090-9-57. [7] Coleman FP.Primary carcinoma of the lung,with invasion of the ribs:pneumonectomy and simultaneous block resection of the chest wall[J].Ann Surg,1947,126(2):156-168.DOI:10.1097/00000658-194708000-00003. [8] Immerman SC,Vanecko RM,Fry WA,et al. Site of recurrence in patients with stages I and Ⅱ carcinoma of the lung resected for cure[J].Ann Thorac Surg,1981,32(1):23-27.DOI:10.1016/S0003-4975(10)61368-9. [9] Sawabata N,Maeda H,Matsumura A,et al. Clinical implications of the margin cytology findings and margin/tumor size ratio in patients who underwent pulmonary excision for peripheral non-small cell lung cancer[J].Surg Today,2012,42(3):238-244.DOI:10.1007/s00595-011-0031-6. [10] Chapelier A,Fadel E,Macchiarini P,et al. Factors affecting long-term survival after en-bloc resection of lung cancer invading the chest wall[J].Eur J Cardiothorac Surg,2000,18(5):513-158.DOI:10.1016/S1010-7940(00)00537-6. [11] Voltolini L,Rapicetta C,Luzzi L,et al. Lung cancer with chest wall involvement:predictive factors of long-term survival after surgical resection[J].Lung Cancer,2006,52(3):359-364.DOI:10.1016/j.lungcan.2006.01.010. [12] Doddoli C,D′Journo B,Le Pimpec-Barthes F,et al. Lung cancer invading the chest wall:a plea for en-bloc resection but the need for new treatment strategies[J].Ann Thorac Surg,2005,80(6):2032-2040.DOI:10.1016/j.athoracsur.2005.03.088. [13] Riquet M,Achour K,Foucault C,et al. Microscopic residual disease after resection for lung cancer:a multifaceted but poor factor of prognosis[J].Ann Thorac Surg,2010,89(3):870-875.DOI:10.1016/j.athoracsur.2009.11.052 [14] Matsuoka H,Nishio W,Okada M,et al. Resection of chest wall invasion in patients with non-small cell lung cancer[J].Eur J Cardiothorac Surg,2004,26(6):1200-1204.DOI:10.1016/j.ejcts.2004.07.038. [15] Wind J,Smit EJ,Senan S,et al. Residual disease at the bronchial stump after curative resection for lung cancer[J].Eur J Cardiothorac Surg,2007,32(1):29-34.DOI:10.1016/j.ejcts.2007.04.003. [16] Ginsberg RJ,Rubinstein LV.Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer[J].Ann Thorac Surg,1995,60(3):615-623.DOI:10.1016/0003-4975(95)00537-U. [17] Hancock JG,Rosen JE,Antonicelli A,et al. Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery[J].Ann Thorac Surg,2015,99(2):406-413.DOI:10.1016/j.athoracsur.2014.09.033. [18] Hanagiri T,Shinohara S,Takenaka M,et al. Clinical characteristics of resected T3 non-small cell lung cancer characterized by parietal pleural invasion or chest wall invasion[J].Indian J Surg,2014,76(5):354-358.DOI:10.1007/s12262-012-0709-z. [19] Borghetti P,Barbera F,Bonù ML,et al. Resected pN1 non-small cell lung cancer:recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy[J].Radiol Med,2016,121(9):696-703.DOI:10.1007/s11547-016-0648-z. [20] Varlotto JM,Yao AN,DeCamp MM,et al. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival[J].Int J Radiat Oncol Biol Phys,2015,91(4):765-773.DOI:10.1016/j.ijrobp.2014.12.028. [21] Mineo TC,Ambrogi V,Pompeo E,et al. Immunohistochemistry-detected microscopic tumor spread affects outcome in en-bloc resection for T3-chest wall lung cancer[J].Eur J Cardiothorac Surg,2007,31(6):1120-1124.DOI:10.1016/j.ejcts.2007.02.021. [22] Kelsey CR,Marks LB,Hollis D,et al. Local recurrence after surgery for early stage lung cancer:an 11-year experience with 975 patients[J].Cancer,2009,115(22):5218-5227.DOI:10.1002/cncr.24625. [23] Patterson GA,Ilves R,Ginsberg RJ,et al. The value of adjuvant radiotherapy in pulmonary and chest wall resection for bronchogenic carcinoma[J].Ann Thorac Surg,1982,34(6):692-697.DOI:10.1016/S0003-4975(10)60911-3. [24] Pitz CC,Brutel de la Rivière A,Elbers HR,et al. Surgical treatment of 125 patients with non-small cell lung cancer and chest wall involvement[J].Thorax,1996,51(8):846-850.DOI:10.1136/thx.51.8.846. [25] Gould PM,Bonner JA,Sawyer TE,et al. Patterns of failure and overall survival in patients with completely resected T3 N0 M0 non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,1999,45(1):91-95.DOI:10.1016/S0360-3016(99)00148-0. [26] Downey RJ,Martini N,Rusch VW,et al. Extent of chest wall invasion and survival in patients with lung cancer[J].Ann Thorac Surg,1999,68(1):188-193.DOI:10.1016/S0003-4975(99)00456-7. [27] Magdeleinat P,Alifano M,Benbrahem C,et al. Surgical treatment of lung cancer invading the chest wall:results and prognostic factors[J].Ann Thorac Surg,2001,71(4):1094-1099.DOI:10.1016/S0003-4975(00)02666-7. [28] Tandberg DJ,Kelsey CR,D′Amico TA,et al. Patterns of failure after surgery for non-small-cell lung cancer invading the chest wall[J].Clin Lung Cancer,2016,18(4):e259-e265.DOI:10.1016/j.cllc.2016.11.008. [29] Osarogiagbon RU,Lin CC,Smeltzer MP,et al. Prevalence,prognostic implications,and survival modulators of incompletely resected non-small-cell lung cancer in the U.S.national cancer data base[J].J Thorac Oncol,2016,11(1):e5-e16.DOI:10.1016/j.jtho.2015.08.002. [30] Choi Y,Lee IJ,Lee CY,et al. Multi-institutional analysis of T3 subtypes and adjuvant radiotherapy effects in resected T3N0 non-small cell lung cancer patients[J].Radiat Oncol J,2015,33(2):75-82.DOI:10.3857/roj.2015.33.2.75. [31] Ettinger DS,Wood DE,Aisner DL,et al. Non-small cell lung cancer,version 5.2017,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2017,15:504-535.DOI:10.6004/jnccn.2017.0050. [32] Wakelee HA,Stephenson P,Keller SM,et al. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages Ⅱ and ⅢA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590[J].Lung Cancer,2005,48(3):389-397.DOI:10.1016/j.lungcan.2004.11.007.
2018, Vol. 27 
